The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema
Top Cited Papers
Open Access
- 12 January 2016
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 39 (2), 179-186
- https://doi.org/10.2337/dc15-1585
Abstract
The current classification system presents challenges to the diagnosis and treatment of patients with diabetes mellitus (DM), in part due to its conflicting and confounding definitions of type 1 DM, type 2 DM, and latent autoimmune diabetes of adults (LADA). The current schema also lacks a foundation that readily incorporates advances in our understanding of the disease and its treatment. For appropriate and coherent therapy, we propose an alternate classification system. The β-cell–centric classification of DM is a new approach that obviates the inherent and unintended confusions of the current system. The β-cell–centric model presupposes that all DM originates from a final common denominator—the abnormal pancreatic β-cell. It recognizes that interactions between genetically predisposed β-cells with a number of factors, including insulin resistance (IR), susceptibility to environmental influences, and immune dysregulation/inflammation, lead to the range of hyperglycemic phenotypes within the spectrum of DM. Individually or in concert, and often self-perpetuating, these factors contribute to β-cell stress, dysfunction, or loss through at least 11 distinct pathways. Available, yet underutilized, treatments provide rational choices for personalized therapies that target the individual mediating pathways of hyperglycemia at work in any given patient, without the risk of drug-related hypoglycemia or weight gain or imposing further burden on the β-cells. This article issues an urgent call for the review of the current DM classification system toward the consensus on a new, more useful system.Keywords
This publication has 88 references indexed in Scilit:
- Influence of Gut Microbiota on Subclinical Inflammation and Insulin ResistanceMediators of Inflammation, 2013
- Thioredoxin-Interacting Protein Mediates ER Stress-Induced β Cell Death through Initiation of the InflammasomeCell Metabolism, 2012
- Exenatide Exerts a Potent Antiinflammatory EffectJournal of Clinical Endocrinology & Metabolism, 2012
- Mechanism of the mitogenic influence of hyperinsulinemiaDiabetology & Metabolic Syndrome, 2011
- The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetesDiabetologia, 2011
- Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and MetforminDiabetes Care, 2010
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes MellitusDiabetes, 2009
- Association between serious ischemic cardiac outcomes and medications used to treat diabetesPharmacoepidemiology and Drug Safety, 2008
- Glucose‐lowering activity of the dipeptidyl peptidase‐4 inhibitor saxagliptin in drug‐naive patients with type 2 diabetes*Diabetes, Obesity and Metabolism, 2008
- Exenatide inhibits β-cell apoptosis by decreasing thioredoxin-interacting proteinBiochemical and Biophysical Research Communications, 2006